Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. (Q51745935)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636089%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

title

Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636089%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636089%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Kirsten Raun

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636089%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Pia von Voss

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636089%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

1 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636089%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636089%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636089%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636089%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

1710-1716

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636089%20AND%20SRC:MED&resulttype=core&format=json

Body composition assessment in extreme obesity and after massive weight loss induced by gastric bypass surgery

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

A role for glucagon-like peptide-1 in the central regulation of feeding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Cardiac function in mice lacking the glucagon-like peptide-1 receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Growth differences of male and female Göttingen minipigs during ad libitum feeding: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Beta-cell function and islet morphology in normal, obese, and obese beta-cell mass-reduced Göttingen minipigs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Diabesity: a polygenic model of dietary-induced obesity from ad libitum overfeeding of Sprague-Dawley rats and its modulation by moderate and marked dietary restriction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Body composition changes following laparoscopic gastric banding for morbid obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Dietary obesity in rats: Body weight and body fat accretion in seven strains of rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

A controlled high-fat diet induces an obese syndrome in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Changes in GI hormones and their effect on gastric emptying and transit times after Roux-en-Y gastric bypass in rat model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Global and societal implications of the diabetes epidemic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

31 March 2020

Epidemiology of diabetes

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204

Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.204